Biospain 2016有望吸引更多美国企业和机构参会

2016-09-06 佚名 Biospain 2016

第八届国际生物科技大会 Biospain 2016 将于9月28日至30日在巴拉卡尔多毕尔巴鄂展览中心举行,本届大会由西班牙生物产业协会 (ASEBIO) 和巴斯克政府经济发展机构 SPRI 联合主办,有望吸引更多美国企业和机构参加。

马德里2016年9月5日电 /美通社/ -- 第八届国际生物科技大会 Biospain 2016 将于9月28日至30日在巴拉卡尔多毕尔巴鄂展览中心举行,本届大会由西班牙生物产业协会 (ASEBIO) 和巴斯克政府经济发展机构 SPRI 联合主办,有望吸引更多美国企业和机构参加。


ASEBIO 主席 Jordi Marti 表示:“我们发现,在我们最近到访的国际展会上,国际投资者和企业群体对解西班牙项目,并将主要位于美国、欧洲和拉美地区的海外公司搬到这里展现出更浓厚的兴趣。”大型制药企业和国际专业投资基金日前宣布在西班牙开设运营部门,这体现了西班牙生物科技公司在科学进展方面正在迎头赶上他们的国际竞争对手。

截至今天,20个国家已确定参加 Biospain 2016。主办方预计本届商业展会的规模将超出上届40%。

Biospain 目前是全球第五大生物科技合作大会,举办的一对一会谈场次达3327场,较2008年 EBD 集团首次推出 partneringONE® 系统以来增长了320%。

Biospain 投资论坛旨在吸引国内外投资者。此次合作将专注于针对投资群体举行特定平行会议和社交活动。

其中最引人注目的主题内容包括有关罕见病、多发性硬化症和患者机构发挥越来越大作用的患者论坛、新的诊断方法、疫苗、老年痴呆症、食品与健康、针对开放式创新的公共政策、纳米生物科技、大数据、新的肿瘤治疗方法和生物经济。

BioSpain 包括商业展会、合作活动、投资论坛、培训与就业论坛、国家和国际演讲人出席的一系列问题相关会议(分组会)以及由科学学会组织的科学会议。就商务会谈场次来说,BioSpain 目前已成为欧洲最大和世界第五大国家级展会。

Biospain 2014吸引了来自37个国家的200家参展商、850多家企业和机构以及1850多名代表参加。一对一商务会谈场次增至3327场(较上届增长20%)。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1989386, encodeId=bfe31989386de, content=<a href='/topic/show?id=7033165e692' target=_blank style='color:#2F92EE;'>#SpA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16576, encryptionId=7033165e692, topicName=SpA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Aug 20 17:23:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917325, encodeId=0456191e325d8, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 09 20:23:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456042, encodeId=61541456042a6, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Thu Sep 08 01:23:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112211, encodeId=d17f112211df, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:43:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112212, encodeId=248a11221248, content=关注科技的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:43:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2017-08-20 gostraight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1989386, encodeId=bfe31989386de, content=<a href='/topic/show?id=7033165e692' target=_blank style='color:#2F92EE;'>#SpA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16576, encryptionId=7033165e692, topicName=SpA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Aug 20 17:23:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917325, encodeId=0456191e325d8, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 09 20:23:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456042, encodeId=61541456042a6, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Thu Sep 08 01:23:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112211, encodeId=d17f112211df, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:43:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112212, encodeId=248a11221248, content=关注科技的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:43:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-10-09 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1989386, encodeId=bfe31989386de, content=<a href='/topic/show?id=7033165e692' target=_blank style='color:#2F92EE;'>#SpA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16576, encryptionId=7033165e692, topicName=SpA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Aug 20 17:23:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917325, encodeId=0456191e325d8, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 09 20:23:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456042, encodeId=61541456042a6, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Thu Sep 08 01:23:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112211, encodeId=d17f112211df, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:43:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112212, encodeId=248a11221248, content=关注科技的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:43:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-08 hyf030
  4. [GetPortalCommentsPageByObjectIdResponse(id=1989386, encodeId=bfe31989386de, content=<a href='/topic/show?id=7033165e692' target=_blank style='color:#2F92EE;'>#SpA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16576, encryptionId=7033165e692, topicName=SpA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Aug 20 17:23:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917325, encodeId=0456191e325d8, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 09 20:23:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456042, encodeId=61541456042a6, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Thu Sep 08 01:23:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112211, encodeId=d17f112211df, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:43:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112212, encodeId=248a11221248, content=关注科技的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:43:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-06 doctorJiangchao

    继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1989386, encodeId=bfe31989386de, content=<a href='/topic/show?id=7033165e692' target=_blank style='color:#2F92EE;'>#SpA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16576, encryptionId=7033165e692, topicName=SpA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Aug 20 17:23:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917325, encodeId=0456191e325d8, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 09 20:23:00 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456042, encodeId=61541456042a6, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Thu Sep 08 01:23:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112211, encodeId=d17f112211df, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:43:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112212, encodeId=248a11221248, content=关注科技的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Sep 06 13:43:00 CST 2016, time=2016-09-06, status=1, ipAttribution=)]
    2016-09-06 doctorJiangchao

    关注科技的进展

    0

相关资讯

美药企污染药品或致脑膜炎暴发

美国检察官办公室新闻发言人17日表示,马萨诸塞州一家联合制药企业14名员工当日早间被逮捕,因该制药企业生产的药物涉嫌导致2012年美国多州脑膜炎疫情暴发并致64人死亡。美国媒体称,这也是美国最严重的一起因药品污染被控的刑事案件。 这家名为新英格兰合成药物中心的制药企业由格里高里·科尼利亚罗和巴里·加顿于1998年创办,位于美国马萨诸塞州东部弗雷明汉镇。美国检察官办公室发言人克里斯蒂娜·斯

基因泰克模式”是制药企业的通用模式吗?

最近包括福布斯Bernard Munos在内的多位生命科学领域的分析家相继发表文章,在批评“Valeant模式”的同时也探讨制药工业的未来发展模式。比如Munos通过计算2011至2015年上市新药占2015年销售额的百分比指出,施贵宝和强生在过去5年开发的新药销售对公司营业额的贡献最大,分别占2015年营业额的39%和22%。相反,过半制药巨头(6个)自2006年之后上市的新药在2015

2015中国制药企业面临的十大风险

2014年第三季度即将过去,距离年底不到100天。全年大势已定,未来出现政策大事件是小概率事件。本文结合当前的形势,简要分析当前及2015年制药企业可能面临的十大风险。